Early-phase clinical drug development of novel agents: a changing paradigm.

Igor Puzanov, Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) Journal of Translational Medicine. ,vol. 13, pp. 1- 2 ,(2015) , 10.1186/1479-5876-13-S1-K8

Caroline Robert, Antoni Ribas, Jedd D Wolchok, F Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S Weber, Anthony M Joshua, Wen-Jen Hwu, Tara C Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A Postow, Kevin Gergich, Jeroen Elassaiss-Schaap, Xiaoyun Nicole Li, Robert Iannone, Scot W Ebbinghaus, S Peter Kang, Adil Daud, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial The Lancet. ,vol. 384, pp. 1109- 1117 ,(2014) , 10.1016/S0140-6736(14)60958-2

Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian, Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Journal of Clinical Oncology. ,vol. 28, pp. 3167- 3175 ,(2010) , 10.1200/JCO.2009.26.7609

Antoni Ribas, F. Stephen Hodi, Margaret Callahan, Cyril Konto, Jedd Wolchok, Hepatotoxicity with Combination of Vemurafenib and Ipilimumab The New England Journal of Medicine. ,vol. 368, pp. 1365- 1366 ,(2013) , 10.1056/NEJMC1302338

David R. Minor, Igor Puzanov, Margaret K. Callahan, Bruce A. Hug, Axel Hoos, Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell & Melanoma Research. ,vol. 28, pp. 611- 612 ,(2015) , 10.1111/PCMR.12383

Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atkins, John D. Powderly, Philip D. Leming, Evan J. Lipson, Igor Puzanov, David C. Smith, Janis M. Taube, Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Drew M. Pardoll, Jeffrey A. Sosman, F. Stephen Hodi, Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Journal of Clinical Oncology. ,vol. 32, pp. 1020- 1030 ,(2014) , 10.1200/JCO.2013.53.0105

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean-Charles Soria, First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors Clinical Cancer Research. ,vol. 18, pp. 4806- 4819 ,(2012) , 10.1158/1078-0432.CCR-12-0742

James Larkin, Paolo A. Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Caroline Dutriaux, Claus Garbe, Mika A. Sovak, Ilsung Chang, Nicholas Choong, Stephen P. Hack, Grant A. McArthur, Antoni Ribas, Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma The New England Journal of Medicine. ,vol. 371, pp. 1867- 1876 ,(2014) , 10.1056/NEJMOA1408868

Jing Yuan Fang, Bruce C Richardson, The MAPK signalling pathways and colorectal cancer. Lancet Oncology. ,vol. 6, pp. 322- 327 ,(2005) , 10.1016/S1470-2045(05)70168-6

Sophie Postel-Vinay, Carlos Gomez-Roca, L. Rhoda Molife, Bhavesh Anghan, Antonin Levy, Ian Judson, Johann De Bono, Jean-Charles Soria, Stan Kaye, Xavier Paoletti, Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities? Journal of Clinical Oncology. ,vol. 29, pp. 1728- 1735 ,(2011) , 10.1200/JCO.2010.31.9236